bioAffinity Technologies, Inc.

bioAffinity Technologies shares have fallen 77% over the past three months, sharply underperforming the industry's 4.5% gain and the broader market. The decline comes despite accelerating commercial sales of its CyPath Lung test, which grew more than 200% year over year in July, and preclinical findings for a novel siRNA-based skin cancer treatment. The company reported mixed first-quarter 2026 results, with strong CyPath Lung growth offset by the discontinuation of lower-margin pathology services, leading to a wider net loss as commercialization and development investments increased. Management highlighted higher unit sales, an expanding base of ordering physicians, and a Department of Defense-supported clinical trial as positive developments, but the stock remains pressured by early-stage commercialization risks, continued operating losses, reliance on equity financing, and dependence on a single product. While the stock's price-to-book ratio of 1.02 times is below the industry average of 3.65 times, analysts note that existing shareholders with higher risk tolerance may consider holding, while prospective investors could wait for clearer signs of sustainable revenue growth and reduced capital needs.